Sherritt Appoints Richard Moat to its Board of Directors
'Richard's expertise leading multinational enterprises through business transformations make him an invaluable addition to our Board,' commented Sir Richard Lapthorne, Chair of Sherritt's Board of Directors. 'We look forward to benefiting from Richard's insights and strategic leadership, leveraging his wealth of experience leading corporations in executive and director positions.'
Sir Richard Lapthorne, continued, 'In addition, I would like to extend my appreciation to Steven for his dedication and diligence in carrying out his role and wish him every success in his future endeavours.'
Richard Moat has a strong track record successfully leading business transformations. Mr. Moat was the Chairman of the Board for Vantiva S.A., formerly Technicolor S.A from 2022 to 2024 and served as CEO of the latter company from 2019 to 2022. Prior to that, he was the CEO of Eir Limited ('Eir'), where he successfully led a turnaround that generated shareholder value in excess of €1 billion. Joining Eir as CFO in 2012, he took the helm as CEO in 2014 through 2018 and was a director from 2018 until 2021. Mr. Moat is a Fellow of the Association of Chartered Certified Accountants. He holds a Diploma in Corporate Finance and Accounting from London Business School and has a master's degree in Law from St Catharine's College, Cambridge.
About Sherritt
Sherritt is a world leader in using hydrometallurgical processes to mine and refine nickel and cobalt – metals deemed critical for the energy transition. Sherritt's Moa Joint Venture has a current estimated mine life of approximately 25 years and is advancing an expansion program focused on increasing annual MSP production by approximately 20% of contained nickel and cobalt. The Corporation's Power division, through its ownership in Energas, is the largest independent energy producer in Cuba with installed electrical generating capacity of 506 MW, representing approximately 10% of the national electrical generating capacity in Cuba. The Energas facilities are comprised of two combined cycle plants that produce low-cost electricity from one of the lowest carbon emitting sources of power in Cuba. Sherritt's common shares are listed on the Toronto Stock Exchange under the symbol 'S'.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Knight Announces Normal Course Issuer Bid
MONTREAL, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company"), a pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the "TSX") of the Company's Notice of Intention to Make a Normal Course Issuer Bid ("NCIB"). Pursuant to the NCIB, the Company proposes to purchase, from time to time over the next 12 months, if considered advisable, up to 3,000,000 common shares of the Company, being approximately 3% of its 99,653,265 common shares issued and outstanding as of August 8, 2025. Purchases may commence on August 22, 2025 and will conclude on the earlier of the date on which purchases under the bid have been completed and August 21, 2026. The Company may purchase up to a daily maximum of 15,823 common shares (being 25% of the average daily trading volume of 63,293 common shares, for the last six calendar months). The common shares may be purchased for cancellation through the facilities of the TSX or through alternative Canadian trading systems at times and in numbers to be determined by the Company. The Company had previously sought and obtained approval from the TSX to purchase up to 5,312,846 common shares under an NCIB and the Company has, in the twelve months preceding this announcement, purchased 2,019,906 common shares through the facilities of the TSX and alternative Canadian trading systems at a weighted average price per share of $5.48. Knight also entered into an automatic share purchase plan with a broker in order to facilitate purchases of its common shares under the NCIB. Under Knight's automatic share purchase plan, Knight's broker may repurchase common shares which it would ordinarily not be permitted to due to regulatory restrictions or self-imposed blackout periods. Purchases will be made by Knight's broker based upon the parameters prescribed by the TSX and applicable Canadian securities laws and the terms of the parties' written agreement. The automatic share purchase plan has been pre-cleared by the TSX and will be implemented effective as of August 22, 2025. The Company believes that the market price of Knight's common shares, from time to time, may not reflect the inherent value of the Company and purchases of common shares pursuant to the bid may represent an appropriate and desirable use of the Company's funds. The price that Knight will pay for Common Shares in open market transactions will be the market price at the time of purchase. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at or Forward-Looking Statement This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2024, as filed on Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law. CONTACT INFORMATION: Investor Contact: Knight Therapeutics Inc. Samira Sakhia Arvind Utchanah President & Chief Executive Officer Chief Financial Officer T: 514.484.4483 T. +598.2626.2344 F: 514.481.4116 Email: IR@ Email: IR@ Website: Website: in to access your portfolio
Yahoo
2 hours ago
- Yahoo
CGI and Kesko enter strategic partnership to accelerate digital transformation
Stock Market Symbols GIB.A (TSX) GIB (NYSE) CGI to leverage global retail expertise to deliver tangible outcomes for Kesko HELSINKI, Finland, Aug. 20, 2025 /PRNewswire/ - CGI (TSX: GIB.A) (NYSE: GIB), one of the largest independent IT and business consulting services firms in the world, and retail services company Kesko have signed an agreement for a strategic partnership to accelerate digital transformation. The partnership covers a wide range of IT services, including end-user services, capacity and cloud services, as well as integrations. In addition, CGI will support the K Group retail network in digital development initiatives. "K Group's goal is to be a forerunner in digital services within the retail sector. In the competitive bidding process, our aim was to find a partner with the best capability to support our business growth and development by leveraging the newest technologies efficiently. The development of automation and AI-based solutions plays a significant role in renewing our business and improving productivity. CGI's strong international expertise combined with local presence convinced us of the company's ability to support us in achieving our objectives," says Arto Hiltunen, CIO at Kesko. "The current trend in the IT sector is that forerunner companies like Kesko are now building strategic collaboration models in which partners participate closely in business development and growth as shared goals and risks. We thank Kesko for the trust in forming a genuine and deep partnership, where the achievement of strategic goals is guided by joint metrics and investments," says Leena-Mari Lähteenmaa, President, CGI Finland, Poland and Baltics. CGI helps retail, consumer and services organizations leverage AI and data-driven strategies to boost profitability by delivering friction-free omnichannel customer experiences, enhancing supply chain agility, streamlining store operations, advancing sustainable transformation, and optimizing IT investments. Read more: About CGIFounded in 1976, CGI is among the largest independent IT and business consulting services firms in the world. With 93,000 consultants and professionals across the globe, CGI delivers an end-to-end portfolio of capabilities, from strategic IT and business consulting to systems integration, managed IT and business process services and intellectual property solutions. CGI works with clients through a local relationship model complemented by a global delivery network that helps clients digitally transform their organizations and accelerate results. CGI Fiscal 2024 reported revenue is CA$14.68 billion and CGI shares are listed on the TSX (GIB.A) and the NYSE (GIB). Learn more at View original content: SOURCE CGI Inc.
Yahoo
2 hours ago
- Yahoo
Xiaomi targets entry into European EV market in 2027
China's Xiaomi Corporation has revealed ambitions to break into the European electric vehicle (EV) market by 2027. This announcement comes on the heels of the company's foray into the EV sector within China, which has seen significant growth over the past year. Xiaomi provided insights into the company's expansion strategy following a notable 30.5% increase in overall quarterly revenue during the June quarter, reaching 116bn yuan ($16.2bn). Its financial report indicated that the company's smart EV, AI, and other initiatives produced 21.3bn yuan in revenue in the second quarter (Q2) 2025. Xiaomi's vehicle deliveries for Q2 2025 stood at 81,302 units, representing a 197.7% year-on-year (YoY) growth compared to the same period in the previous year. The company's network of EV sales centres has also expanded, with 335 locations now spread across 92 cities, and a net addition of 100 sales centres quarter over quarter. The EV division's losses have narrowed to approximately 300m yuan during the quarter. Additionally, the gross margin for Xiaomi's businesses, which includes smart EVs and AI, improved to 26.4% in Q2, up from 15.4% in the previous year period. According to data from the China Association of Automobile Manufacturers (CAAM), sales of Chinese-made vehicles, including exports, experienced a near 15% YoY increase to 2.593 million units in July 2025. This comes after a 5% decline to 2.262 million units the year before. Domestic sales saw a 13% rise to 2.018 million units, while exports surged by 23% to 575,000 units. In June, Xiaomi launched the YU7, its first battery-powered SUV model. The launch was a significant event for Xiaomi's automotive business, with local reports indicating that the automaker received over 200,000 confirmed orders for the new model within an hour of its unveiling. Furthermore, in the same month, Xiaomi secured a 50-year lease for a 485,134m2 plot of land in Beijing, China, for smart connected car and components projects. The Beijing municipal planning and natural resources commission announced the deal, valued at 635m yuan ($88m). In March, Xiaomi agreed to raise $5.5bn through a placement and subscription agreement involving the sale and issuance of 800 million shares. "Xiaomi targets entry into European EV market in 2027" was originally created and published by Just Auto, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
